Old Web
English
Sign In
Acemap
>
authorDetail
>
Ahmed Tawashi
Ahmed Tawashi
Ibrutinib
Cancer research
Bruton's tyrosine kinase
Tyrosine kinase
Durvalumab
3
Papers
9
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Ibrutinib + durvalumab (MEDI4736) in patients (pts) with relapsed or refractory (R/R) pancreatic adenocarcinoma (PAC): A phase Ib/II multicenter study.
2016
Journal of Clinical Oncology
Erkut Borazanci
David Sanghyun Hong
Martin Gutierrez
Drew W. Rasco
Tony Reid
Michael H. Veeder
Ahmed Tawashi
Jennifer C. Lin
Isaiah W. Dimery
Show All
Source
Cite
Save
Citations (8)
Abstract B42: Ibrutinib in combination with durvalumab (MEDI4736) in patients with relapsed or refractory HER2-positive or triple-negative breast cancer: A phase 1b/2 multicenter study
2016
Molecular Cancer Research
Drew W. Rasco
Erkut Borazanci
Martin Guiterrez
David S. Hong
Ahmed Tawashi
Jennifer C. Lin
Isaiah W. Dimery
Mark Fosdale
Show All
Source
Cite
Save
Citations (0)
A multicenter, open-label phase 2a study of ibrutinib with or without cytarabine in patients with acute myeloid leukemia (PCYC-1131).
2015
Journal of Clinical Oncology
Jorge E. Cortes
Elihu H. Estey
Anthony S. Stein
Thorsten Graef
Nora Cavazos
Taisei Kinoshita
Ying Luan
Ahmed Tawashi
Show All
Source
Cite
Save
Citations (1)
1